-
-
-
-
-
-
-
Ocular Therapeutix™ Investor Day to Highlight U.S. FDA Alignment on AXPAXLI™ NDA with Submission Planned for Fourth Quarter 2026
-
-
-
-
-
-
-
Ocular Therapeutix™ Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI™ in Wet AMD
-
-
-
-
-
-
-
Ocular Therapeutix plans to accelerate AXPAXLI submission for wet AMD
-
-
-
-
-
-
-
Ocular Therapeutix™ Achieves Target Randomization of 555 Subjects in SOL-R
-
-
-
-
-
-
-
Raymond James Reiterates Strong Buy Rating on Ocular Therapeutix (OCUL)
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Ocular Therapeutix (OCUL)
-
-
-
-
-
-
-
Ocular Therapeutix (OCUL) PT Raised to $15 at H.C. Wainwright
-
1,225,067 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

